Loperamide Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Antidiarrhoeal
Subclass
Peripheral opioid receptor agonist
Speciality
Gastroenterology
Schedule (India)
Schedule H
Routes
Oral
Formulations
- 2 mg tablets
- 2 mg capsules
- 1 mg/5 mL oral suspension
Adult indications
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Acute Non-specific Diarrhoea (Adults)
| Parameter | Recommendation |
|---|---|
| Starting dose | 4 mg (2 tablets/capsules) initially |
| Titration | 2 mg after each unformed stool |
| Usual maintenance dose | 4–8 mg/day |
| Maximum dose | 16 mg/day |
Clinical Notes:
- Do not exceed 48 hours of treatment without clinical reassessment
- Discontinue if no improvement within 48 hours
- Ensure adequate oral rehydration alongside antimotility therapy
2. Chronic Diarrhoea (e.g., IBS-D, Short Bowel Syndrome)
| Parameter | Recommendation |
|---|---|
| Starting dose | 4 mg/day in divided doses |
| Titration | Increase by 2 mg/day based on response |
| Usual maintenance dose | 4–8 mg/day in 2–4 divided doses |
| Maximum dose | 16 mg/day |
Clinical Notes:
- If no improvement after 10 days, reassess diagnosis and management
- Long-term use may help reduce stool frequency but does not address bloating or abdominal discomfort
- Consider specialist referral for persistent symptoms
3. Diarrhoea Associated with Ileostomy
| Parameter | Recommendation |
|---|---|
| Starting dose | 4 mg/day in divided doses |
| Titration | Adjust based on stoma output |
| Usual maintenance dose | 4–8 mg/day |
| Maximum dose | 16 mg/day |
Clinical Notes:
- Aim to reduce excessive stoma output and fluid losses
- Gastroenterology or surgical specialist supervision recommended
- Monitor hydration and electrolyte status regularly
Secondary Indications — Adults (Off-label, if any)
| Indication | Dose | Duration | Label Status | Evidence Basis |
|---|---|---|---|---|
| Traveller's Diarrhoea | Starting: 2–4 mg stat; then 2 mg after each loose stool; Max: 16 mg/day | Short-term only (≤48 hours) | OFF-LABEL | Indian specialist practice; limited RCT data |
Cautions for Off-label Use:
- Avoid in presence of fever, bloody stools, or suspected invasive bacterial infection (Shigella, Salmonella, EHEC)
- Risk of ileus increases with invasive pathogens
- Use only as adjunct to rehydration and antimicrobials where indicated
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indication: Acute Diarrhoea
| Age Group | Weight Range | Dose | Maximum Daily Dose |
|---|---|---|---|
| <2 years | Any |
NOT RECOMMENDED
|
— |
| 2–5 years | 13–20 kg | 1 mg (5 mL) twice daily | 6 mg/day |
| 6–8 years | 20–30 kg | 2 mg/day in 2 divided doses | 8 mg/day |
| 9–12 years | >30 kg | 2 mg three times daily | 8 mg/day |
Duration: Not more than 2–3 days without clinical reassessment
Safety Monitoring:
- Discontinue immediately if abdominal distension or reduced bowel sounds develop
- Monitor hydration status and serum electrolytes
- Exercise extra caution in malnourished or significantly dehydrated children
- Oral rehydration remains the cornerstone of diarrhoea management in children
Secondary Indications — Paediatrics (Off-label, if any)
| Indication | Dose | Duration | Label Status | Evidence Basis |
|---|---|---|---|---|
| Chronic diarrhoea in short bowel syndrome | Titrated individually | Long-term under supervision | OFF-LABEL; Specialist only | Limited paediatric case series; Indian GI specialist practice |
Age Restriction:
- Not recommended in children below 2 years due to risk of paralytic ileus and fatal respiratory depression
Renal Adjustments
No dose adjustment required.
Hepatic adjustment
Contraindications
- Age below 2 years
- Acute dysentery (bloody or mucoid stools)
- Febrile diarrhoea or suspected invasive bacterial enteritis
- Pseudomembranous colitis (Clostridioides difficile infection)
- Known hypersensitivity to loperamide or any excipients
- Severe hepatic impairment
Cautions
- HIV-positive patients with diarrhoea (risk of toxic megacolon if underlying infectious colitis)
- Elderly patients (increased risk of constipation and bowel distension)
- Dehydrated or malnourished patients
- Prolonged or repeated use may delay diagnosis of underlying pathology
- Extended use can cause rebound constipation
Pregnancy
| Parameter | Recommendation |
|---|---|
| Risk category | Generally considered safe based on available data; limited human studies |
| Preferred alternative | Oral rehydration therapy is first-line |
| When may be used | Short-term use under obstetric guidance if rehydration alone is insufficient |
| Monitoring | Watch for signs of constipation and reduced gut motility |
Lactation
| Parameter | Recommendation |
|---|---|
| Compatibility | Compatible with breastfeeding |
| Drug levels in milk | Very low |
| Preferred status | Preferred over diphenoxylate-atropine combinations |
| Infant monitoring | Observe for constipation, reduced feeding, or unusual drowsiness |
Elderly
- Starting dose: Begin at 2 mg; titrate cautiously
- Titration: Slower than in younger adults
- Extra risks: Increased susceptibility to constipation, paralytic ileus, and abdominal distension
- Monitoring: Regularly assess bowel sounds and abdominal examination
Major drug interactions
| Interacting Drug/Class | Mechanism/Effect | Recommendation |
|---|---|---|
| P-glycoprotein inhibitors (quinidine, ritonavir, verapamil) | Increased CNS penetration of loperamide | Avoid combination; CNS depression risk |
| Strong CYP3A4/CYP2C8 inhibitors (ketoconazole, itraconazole, gemfibrozil) | Elevated loperamide plasma levels | Avoid or use with extreme caution |
| QT-prolonging drugs (at high loperamide doses) | Additive QT prolongation | Risk of torsades de pointes; avoid supratherapeutic dosing |
Moderate drug interactions
| Interacting Drug/Class | Mechanism/Effect | Recommendation |
|---|---|---|
| CNS depressants (benzodiazepines, opioids) | Additive sedation (mainly at abuse-level doses) | Monitor for excessive drowsiness |
| Anticholinergic drugs | Increased risk of paralytic ileus | Unidentified |
| Oral cholera vaccine | Reduced vaccine immunogenicity | Avoid concurrent administration |
Common Adverse effects
- Constipation
- Abdominal cramps
- Nausea
- Flatulence
- Dizziness
- Dry mouth
Serious Adverse effects
- Toxic megacolon (especially if used in infectious colitis)
- Paralytic ileus
- CNS depression (particularly in hepatic impairment or overdose/abuse)
- QT prolongation and ventricular arrhythmias (reported with supratherapeutic doses or abuse)
- Anaphylaxis (rare)
Monitoring requirements
| Timing | Parameters |
|---|---|
| Baseline | Hydration status, serum electrolytes, clinical assessment for invasive infection |
| After initiation | Bowel sounds, abdominal distension, stool frequency |
| Chronic use | Bowel pattern, CNS symptoms (if hepatic dysfunction suspected), electrolyte balance |
Brands in India
- Lopedim® (Cipla)
- Imodium® (Janssen)
- Lopamide®
- Lomedon®
Note: Lomotil® contains diphenoxylate-atropine — it is a different drug.
Price range (INR)
| Formulation | Approximate Price |
|---|---|
| Tablets (2 mg) | ₹1–₹3 per tablet |
| Capsules (2 mg) | ₹1–₹3 per capsule |
| Oral suspension (30 mL) | ₹20–₹35 per bottle |
NLEM Status: Not included in NLEM 2022; price variation exists across brands.
Clinical pearls
- Always exclude invasive bacterial diarrhoea (fever, blood/mucus in stool) before prescribing — loperamide is contraindicated in such cases
- In acute diarrhoea, treatment beyond 48 hours without reassessment is inappropriate
- For IBS-D, low-dose loperamide may reduce stool frequency but has limited effect on bloating or pain
- Avoid in patients with hepatic impairment — reduced first-pass metabolism increases CNS toxicity risk
- Contraindicated below age 2 years due to risk of serious respiratory and GI complications
- Be vigilant for loperamide abuse (high doses for opioid effects) — associated with fatal cardiac arrhythmias
Version
'
RxIndia v1.0 — 28 May 2025
Reference
-
- CDSCO product listings
- Indian Pharmacopoeia
- AIIMS Formulary
- API Textbook of Medicine
- ICMR Guidelines on Diarrhoeal Management
- National Treatment Guidelines for Acute Diarrhoea (Government of India)
- WHO Model List of Essential Medicines (supportive reference)
- NLEM 2022 (drug status verified — not listed)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.